Accelerated rejection of FAS ligand-expressing heart grafts

Journal of Immunology

Volumn 162, Issue 1, 1999, Pages 518-522

  Takeuchi, Takumi ^a   Ueki, Tetsuo ^a   Nishimatsu, Hiroaki ^a   Kajiwara, Takahiro ^a   Ishida, Toshimitsu ^a   Jishage, Kou Ichi ^a   Ueda, Otoya ^b   Suzuki, Hiroshi ^b   Li, Baoxing ^a   Moriyama, Nobuo ^a   Kitamura, Tadaichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; LIGAND BINDING; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIGENS, CD95; FAS LIGAND PROTEIN; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; LIGANDS; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, TRANSGENIC; TRANSGENES;

EID: 0032961753     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Nagata, S., and T. Suda. 1995. Fas and Fas ligand: lpr and gld mutations. Immunol. Today 16:39.
2. Ferguson, T. A., and T. S. Griffith. 1997. A vision of cell death: insights into immune privilege. Immunol. Rev. 156:167.
3. Bellgrau, D., D. Gold, H. Selawry, J. Moore, A. Franzusoff, and R. C. Duke. 1995. A role for CD95 ligand in preventing graft rejection. Nature 377:630.
4. Seino, K., N. Kayagaki, K. Okumura, and H. Yagita. 1997. Antitumor effect of locally produced CD95 ligand. Nat. Med. 3:165.
5. Kang, S. M., D. B. Schneider, Z. Lin, D. Hanahan, D. A. Dichek, P. G. Stock, and S. Baekkeskov. 1997. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat. Med. 3:738.
6. Arai, H., D. Gordon, E. G. Nabel, and G. J. Nabel. 1997. Gene transfer of Fas ligand induces tumor regression in vivo. Proc. Natl. Acad. Sci. USA 94:13862.
7. Takahashi, T., M. Tanaka, C. T. Brannan, N. A. Jenkins, N. G. Copeland, T. Suda, and S. Nagata. 1994. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 76:969.
8. Niwa, H., K. Yamamura, and J. Miyazaki. 1991. Efficient selection for high-expression transfectant with a novel eukaryotic vector. Gene 108:193.
9. Gulick, J., A. Subramaniam, J. Neumann, and J. Robbins. 1991. Isolation and characterization of the mouse cardiac myosin heavy chain genes. J. Biol. Chem. 266:9180.
10. Subramaniam, A., W. K. Jones, J. Gulick, S. Wert, J. Neumann, and J. Robbins. 1991. Tissue-specific regulation of the α-myosin heavy chain gene promotor in transgenic mice. J. Biol. Chem. 266:24613.
11. Nohmi, T., M. Katoh, H. Suzuki, M. Matsui, M. Yamada, M. Watanabe, M. Suzuki, N. Horiya, O. Ueda, T. Shibuya, H. Ikeda, and T. Sofuni. 1996. A new transgenic mouse mutagenesis test system using spi- and 6-thioguanine selection. Environ. Mol. Mutagen. 28:465.
12. Takeuchi, T., T. Ueki, S. Sunaga, K. Ikuta, Y. Sasaki, B. Li, N. Moriyama, J. Miyazaki, and K. Kawabe. 1997. Murine IL-4 transgenic heart allograft survival prolonged with downregulation of Th1 cytokine mRNA in grafts. Transplantation 64:152.
13. Corry, R. J., H. J. Winn, and P. S. Russell. 1973. Primarily vascularized allografts of hearts in mice: the role of H-2D, H-2K, and non-H-2 antigens in rejection. Transplantation 16:343.
14. Hansen, P. R. 1995. Role of neutrophils in myocardial ischemia and reperfusion. Circulation 91:1872.
15. Seino, K., N. Kayagaki, N. Tsukada, N. Fukao, H. Yagita, and K. Okumura. 1997. Transplantation of CD95 ligand-expressing grafts: influence of transplantation site and difficulty in protecting allo- and xenografts. Transplantation 64: 1050.
16. Strand, S., W. J. Hofmann, H. Hug, M. Muller, G. Otto, D. Strand, S. M. Mariani, W. Stremmel, P. H. Krammer, and P. R. Galle. 1996. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand expressing tumor cells: a mechanism of immune evasion? Nat. Med. 2:1361.
17. O'Connell, J., G. C. O'Sullivan, J. K. Collins, and F. Shanahan. 1996. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med. 184:1075.
18. Zeytun, A., M. Hassuneh, M. Nagarkatti, and P. S. Nagarkatti. 1997. Fas-Fas ligand-based interactions between tumor cells and tumor-specific cytotoxic T lymphocytes: a lethal two-way street. Blood 90:195.